COVID-19 Global Updates & Resources

This study is a multicenter randomized, double-blind trial conducted through Wuhan Union Hospital, China, where participants are divided into two groups to analyze the efficacy and safety of using recombinant TPO agents (rhTPO) and eltrombopag to treat primary ITP in adult patients. In one group, participants can expect to receive a subcutaneous rhTPO agonist injection or an oral placebo tablet. In the second group, participants can expect to receive oral eltrombopag or a placebo injection. This study will only include adult ITP patients between the ages of 18 years – 75 years in good health.

China

https://www.clinicaltrials.gov/ct2/show/NCT03771378?cond=Immune+Thrombocytopenia&draw=2&rank=34

Recruiting